[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645036":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":66,"collaborators":26,"id":69,"slug":26,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Fakih IVF Fertility Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"thymosin-α1","EXPERIMENTAL","Thymosin α1 in recurrent implantation failure patients",[13],"Drug: Thymosin Alpha1",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo arm.",[19],"Other: Placebo Control",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Thymosin Alpha1","Start at luteal start in ART cycles and continue until 10+6 weeks' gestation.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo Control","Matching placebo injections on the same schedule and duration.",[15],[32],{"name":33,"affiliation":34,"role":35},"Michael Fakih, MD","Fakih IVF Abu Dhabi","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Dr. Lamiya Mohiyiddeen, MD, FRCOG","CONTACT","+971543676002","lamiya.mohiyiddeen@fakihivf.com",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"Fatma Bathawab, PhD","+971585707393","fatma.bathawab@fakihivf.com",[47],{"facility":48,"status":49,"city":50,"state":26,"zip":26,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Fakih IVF","RECRUITING","Abu Dhabi","United Arab Emirates","AE",{"type":54,"coordinates":55},"Point",[56,57],54.39696,24.45118,{"lat":57,"lon":56},[60,64],{"name":61,"role":39,"phone":62,"phoneExt":26,"email":63},"Dr. Lamiya Mohiyiddeen","0585707393","lamiya.mohiyiddeen@firstivf.ae",{"name":65,"role":39,"phone":26,"phoneExt":26,"email":45},"Fatma Bathawab",{"type":35,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Lamiya Mohiyiddeen","Research Director, Research Ethics Committee Chair","100645036",false,"NCT07675980","Thymosin-α1 for Recurrent Implantation Failure","Thymosin-α1 for Recurrent Implantation Failure Following Transfer of PGT-a Tested Embryo: A Randomized, Double-Blind, Placebo-Controlled Trial","Thy-α1 for RIF","Inclusion Criteria:\n\n1. -Women 18-40 years\n2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos\n3. \\- Normal parental karyotypes\n4. \\- Normal uterine cavity on imaging\n5. \\- Negative antiphospholipid panel\n6. \\- Thyroid and prolactin controlled within local reference standards\n\nExclusion Criteria:\n\n1. Identified\u002Fcorrectable non-immune cause of RPL (chromosomal, anatomic, endocrine)\n2. \\- Active malignancy\n3. -Active infection\n4. \\- Uncontrolled systemic disease\n5. \\- Current systemic immunosuppression","FEMALE","18 Years","40 Years",{"count":80,"type":81},136,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE2","PHASE3","Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF\u002FICSI cycles.",[88],"Recurrent Implantation Faliure",[90,91,92,93],"Thymosin","recurrent implantation failure","Thymosin alpha","PGT-a tested embryos","2026-06-29",{"date":96,"type":97},"2026-06-30","ACTUAL",{"date":99,"type":97},"2026-02-11",{"date":101,"type":81},"2027-06",{"name":5,"class":6},1]